Company intelligence / Profile preview
Prestige Biopharma Limited
Singapore, Singaporeprestigebiopharma.com ↗
- Ownership
- Private
- Employees
- ~54
- Development stage
- Other
01
Overview
Prestige Biopharma reported its first-ever net profit of 32.1 billion won ($22 million) for the second half of 2024, primarily fueled by milestone payments from Tuznue (trastuzumab), its Herceptin biosimilar which received European approval in 2024[7]. The company has a diverse portfolio of biosimilars and novel antibody drugs in various stages of development.
- Therapeutic areas
- OncologyImmunologyEndocrinologyInfectious Diseases
- Modalities
- Monoclonal antibodies (mAbs)Bispecific antibodies (bsAbs)Fusion protein antibodies (fusion-Abs)BiosimilarsVaccines
- Industry
- Biotech
02
Drug pipeline
28 assets27 more assets in the full pipeline.
03
Partnerships
Dr. Reddy's
Beyond the preview
Go deeper on Prestige Biopharma Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prestige Biopharma Limited.